Insulin resistance index and counter-regulatory factors during olanzapine or risperidone administration in subjects with schizophrenia

Schizophrenia Research

Volumn 89, Issue 1-3, 2007, Pages 350-352

  Baptista, Trino ^a   Martinez, Maritza ^a   Lacruz, Anny ^a   Arellano, Antonio ^b   Mendoza, Soaira ^c   Beaulieu, Serge ^d   Hernández, Luis ^a   Contreras, Quilianio ^e   Galeazzi, Tatiana ^a   Vargas, Doritza ^a  

^a Universidad De Los Andes Facultad de Medicina   (Venezuela)

^b Psychiatric Institute Dr Ra Ú L Castillo   (Venezuela)

^c Metabolism Center   (Venezuela)

^d MCGILL UNIVERSITY   (Canada)

^e Universidad Experimental de Santa Bárbara   (Venezuela)

Author keywords

[No Author keywords available]

Indexed keywords

ADRENALIN; APPETITE STIMULANT; CLOZAPINE; FLUPHENAZINE DECANOATE; INSULIN; INSULIN COUNTER REGULATORY FACTOR; LEPTIN; NEUROLEPTIC AGENT; OLANZAPINE; REGULATOR PROTEIN; RISPERIDONE; TUMOR NECROSIS FACTOR ALPHA;

BODY MASS; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG WITHDRAWAL; FEMALE; GLUCOSE BLOOD LEVEL; GLUCOSE BRAIN LEVEL; GLUCOSE DYSREGULATION; GLUCOSE TRANSPORT; GLYCOGEN SYNTHESIS; HUMAN; HYPERGLYCEMIA; INSULIN RELEASE; INSULIN RESISTANCE; INSULIN SENSITIVITY; LETTER; MALE; PRIORITY JOURNAL; SCHIZOPHRENIA; SIDE EFFECT; WEIGHT GAIN;

ADULT; ANTIPSYCHOTIC AGENTS; APPETITE; BENZODIAZEPINES; BLOOD GLUCOSE; CHRONIC DISEASE; DELAYED-ACTION PREPARATIONS; FEMALE; FLUPHENAZINE; HUMANS; INSULIN; INSULIN RESISTANCE; MALE; REFERENCE VALUES; RISPERIDONE; SCHIZOPHRENIA; WEIGHT GAIN;

EID: 33845298594     PISSN: 09209964     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.schres.2006.08.020     Document Type: Letter

References (5)

1. Baptista T. Antipsychotic drugs, weight gain and diabetes. In: Hofbauer K.-G., Keller U., and Boss O. (Eds). Pharmacotherapy of Obesity: Options and Alternatives (2004), Florida: CRC Press, Florida, USA chap 4
2. Bastard J.P., Maachi M., Lagatho C., Kim M.J., Caron M., Vidal H., Capeau J., and Feve B. Recent advances in the relationship between obesity, inflammation, and insulin resistance. Eur. Cytokine Netw. 17 1 (2006) 4-12
3. Dwyer D.S., Donohoe D., Lu X.H., and Aamodi E.J. Mechanistic connections between glucose/lipid disturbances and weight gain induced by antipsychotic drugs. Int. Rev. Neurobiol. 65 (2005) 211-247
4. Elman L., Borsook D., and Lukas S.E. Food intake and reward mechanisms in patients with schizophrenia: implications for metabolic disturbances and treatment with second-generation antipsychotic agents. Neuropsychopharmacology 31 (2005) 2091-2120
5. Henderson D.C. Atypical antipsychotic-induced diabetes mellitus. CNS Drugs 16 2 (2002) 77-89